Kaveh Jaseb

Kaveh Jaseb

Auto-generated profile, based on publicly available information

Kaveh Jaseb

Thalassemia & Hemoglobinopathy Research Center, Health Research Institute Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2013 in Oncology Reviews
Verified
Journal Article
Open access
PDF file
ARAli Hosseini Rad
Ali Hosseini Rad
MBMahsa Shanaki Bavarsad
Mahsa Shanaki Bavarsad
EAEhsan Arefian
Ehsan Arefian
KJKaveh Jaseb
Kaveh Jaseb
MSMohammad Shahjahani
Mohammad Shahjahani
NNajmaldin Saki
Najmaldin Saki
Cancer is one of the most important diseases of humans, for which no cure has been found so far. Understanding the causes of cancer can pave the way for its treatment. Alteration in genetic elements such as oncogenes and tumor suppressor genes results in cancer. The most recent theory for the origin of cancer has been provided by cancer stem cells (CSCs). Tumor-initiating cells (T-ICs) or CSCs are a small population isolated from tumors and hematologic malignancies. Since CSCs are similar to embryonic stem cells (ESCs) in many aspects (such as pluripotency and self-renewal), recognizing the signaling pathways through which ESCs maintain their stemness can also help identify CSC signaling. One component of these signaling pathways is non-coding RNAs (ncRNAs). ncRNAs are classified in two groups: microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). miRNAs undergo altered expression in cancer. In this regard, they are classified as Onco-miRNAs or tumor suppressor miRNAs. Some miRNAs play similar roles in ESCs and CSCs, such as let-7 and miR-302. This review focuses on the miRNAs involved in stemness of ESCs and CSCs by presenting a summary of the role of miRNAs in other tumor cells.

12 April 2014 in Hematology
Verified
Journal Article
Closed access
SAShirin Azizidoost
Shirin Azizidoost
MBMehrnoosh Shanaki Bavarsad
Mehrnoosh Shanaki Bavarsad
SSSaeid Shahrabi
Saeid Shahrabi
KJKaveh Jaseb
Kaveh Jaseb
FRFakher Rahim
Fakher Rahim
NNajmaldin Saki
Najmaldin Saki
Bone marrow (BM) niche is a three-dimensional structure composed of a series of cells and it is one of the most controversial topics in hematological malignancies, leukemia, and even metastasis. Here, we review the relationship between Notch signaling and different fates of stem cells and other BM niche cells. Relevant English-language literature were searched and retrieved from PubMed (2000-2013) using the terms Notch signaling, BM niche, and microRNAs (miRNAs). Notch signaling pathway is a signaling system involved in cellular processes such as proliferation, differentiation, and apoptosis. The notch signaling pathway components are associated with interaction between leukemic, metastatic, and normal cells and their microenvironment. miRNAs play an important role in expression and regulation of signaling molecules. It is necessary to evaluate the relationship between aberrant miRNA expression and notch signaling such as miR-128 and miR-30 in glioma and angiogenesis with notch signaling, respectively. Characterizing malignant cells and future studies focus on better understanding the variety of cancers and apoptosis with activated Notch signaling pathway, may remain promising this signaling system as a safe and effective therapeutic target.

1 December 2017 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
PDF file
HRHadi Rezaeeyan
Hadi Rezaeeyan
KJKaveh Jaseb
Kaveh Jaseb
AAARASH Alghasi
ARASH Alghasi
AAAli Amin Asnafi
Ali Amin Asnafi
NNajmaldin Saki
Najmaldin Saki
Immune thrombocytopenic purpura (ITP) is an autoimmune disease in which increased platelet destruction and thrombocytopenia are diagnostic features. In fact, the exact pathogenesis of this disease is still unknown, but genetic changes can be a potential factor in the development of ITP. In this study, the relationship between polymorphisms with platelet destruction has been studied, which leads to decreased platelet count. Relevant literature was identified by a PubMed search (2000–2016) of English language papers using the terms ‘ITP’, ‘polymorphism,’ and ‘immune system’. The majority of genetic changes (polymorphisms) occur in immune system genes, including interferon (IFN)-γ gene. These changes lead to the dysfunction of immune system and production of pathogenic antibodies against platelet surface glycoproteins such as glycoprotein IIb/IIIa, which eventually result in the destruction of platelets and increasing disease severity. In addition, IFN-γ as well as factors and cytokines involved in megakaryopoiesis, including stem cell factor and interleukin-3 (IL-3), leads to the differentiation of megakaryocytes and platelet release. Considering the fact that IFN-γ is a factor of inflammation and thrombocytopenia, coexistence of this cytokine with thrombopoietin, stem cell factor, and IL-3 results in megakaryocytes differentiation and platelet production, which can be effective to reduce disease severity and increase the platelet counts.

23 September 2014 in Oncology Reviews
Verified
Journal Article
Open access
PDF file
AAAhmad Ahmadzadeh
Ahmad Ahmadzadeh
SSSaeid Shahrabi
Saeid Shahrabi
KJKaveh Jaseb
Kaveh Jaseb
FNFatemeh Norozi
Fatemeh Norozi
MSMohammad Shahjahani
Mohammad Shahjahani
NNajmaldin Saki
Najmaldin Saki
BRAF is a serine/threonine kinase with a regulatory role in the mitogen-activated protein kinase (MAPK) signaling pathway. A mutation in the RAF gene, especially in BRAF protein, leads to an increased stimulation of this cascade, causing uncontrolled cell division and development of malignancy. Several mutations have been observed in the gene coding for this protein in a variety of human malignancies, including hairy cell leukemia (HCL). BRAF V600E is the most common mutation reported in exon15 of BRAF, which is observed in almost all cases of classic HCL, but it is negative in other B-cell malignancies, including the HCL variant. Therefore it can be used as a marker to differentiate between these B-cell disorders. We also discuss the interaction between miRNAs and signaling pathways, including MAPK, in HCL. When this mutation is present, the use of BRAF protein inhibitors may represent an effective treatment. In this review we have evaluated the role of the mutation of the BRAF gene in the pathogenesis and progression of HCL.

1 January 2013
Verified
Journal Article
Open access
AFAli Dehghani Fard
Ali Dehghani Fard
SHSeyed Ahmad Hosseini
Seyed Ahmad Hosseini
MSMohammad Shahjahani
Mohammad Shahjahani
FSFatemeh Salari
Fatemeh Salari
KJKaveh Jaseb
Kaveh Jaseb
The use of fetal hemoglobin (HbF) inducer drugs is considered as a novel approach in treatment of β-hemoglobinopathies, especially β- thalassemia and sickle cell disease. HbF inducers including hydroxyurea, histone deacetylase (HDAC) inhibitor agents such as sodium butyrate, azacitidine, decitabine and new immunomodulator drugs like pomalidomide, lenalidomide and thalidomide can reduce α-globin chain production in erythroid progenitors and improve α: β chain imbalance, the most crucial complication of β-thalassemia. In this article, we reviewed more than 40 articles published from 1979 to 2012 in the field of fetal hemoglobin augmentation. Recent studies suggest the synergistic effect of drug combinations in efficient induction of fetal hemoglobin and gene over-expression. It seems that drugs which act with different molecular and epigenetic mechanisms have proper synergistic effects in fetal hemoglobin induction and gene over-expression.

1 January 2015 in Genetics and Molecular Research
Verified
Journal Article
Closed access
SYS. Yazdanparast
S. Yazdanparast
SKS.R. Khatami
S.R. Khatami
HGH. Galehdari
H. Galehdari
KJK. Jaseb
K. Jaseb
The PAX5 gene, which encodes the B-cell specific activator protein, is one of the most important factors in determination of B-cell development. This gene is the main target of somatic mutations in acute B lymphoblastic leukemia (B-ALL). For example, point mutations, deletions, as well as other gene rearrangements may lead to several forms of B-cell malignancy. In this study, we obtained 50 blood samples from patients diagnosed with ALL, and screened for PAX5 mutations using sequencing in exons 1, 2 and 3. We found a heterozygous germline variant, c.113G>A (p.Arg38His), which affects the paired domain of PAX5. It seems that this mutation is pathogenic, but is recessive. Our findings suggest that this mutation in a single allele of the PAX5 gene is not sufficient to cause disease, and it is possible that other alleles are also involved in the onset of B-ALL.